wer hat news zu immune response - 500 Beiträge pro Seite

[Lena97]

sieht heute schlecht aus für immune response. hat jemand facts, die kursrückgang begründen???
danke!!

[tommyb]

Allgemeiner Absturz der Biotechaktien in den USA....

[Corbu]

Die Aktie dümpelte letzte Woche vor sich hin und ich dachte die Ruhe vor dem Sturm.
Habe für 10,50 Euro gekauft.
Wie geht es weiter?

[bobysmith]

hi allerseits,

ich versteh nun gar nichts mehr. über den aids-kongress in südafrika hatte ich mir eigentlich positive publicity versprochen - nun ist genau das gegenteil eingetreten (kurstechnisch.

wir müssem wohl weiter warten und auf "good news" bezüglich thailand hoffen.

bis dann
b.s.

[03516]

Immune Response (IMNR) - News


Friday, 28 Jul 2000, 11:19 AM EDT, Comtex News Service



Analyst Opinions
Strong Buy
2
Buy
0
Hold
0
Sell
0
Strong Sell
0


Average
Recommendation
This Week
1
Last Week
1
Change
0.0
Recommendation Scale
Strong
Sell
Hold
Strong
Buy
5.0
3.0
1.0
Immune Response Corp. ranks 2 of 114 in the MED-DRUGS industry

[Lena97]

hallo 03516

deine analystenmeinungen geben ja wieder hoffnung für diesen wert. der aktuelle kurs allerdings nicht. dachte nach südafrika würde es wieder aufwärts gehen. na ja hoffen wir auf good news

[jaccomoI]

Kurs in USA $7,50

Taxe in Frankfurt 8,50 zu 9,00 Letzter Kauf 3000 Stück zu 8,50.

Geht es wieder aufwärts? News?

[jaccomoI]

Heute geht der Punk ab bei IMNR.

630.000 Stücke in USA innerhalb 20 Minuten gehandelt.

Mein heutiges Ziel $8,50.

Good trades.

[bobysmith]

ja, ja, ja,

genau das erwart ich von dieser aktie, wenn alle 7 $ bid-position weg befriedigt sind, dann geht`s nach oben!!!!!

nur weiter so "imunnechen"

bob smith

[Stricher]

Wenn ich die Nachricht auf www.nasdaq.com richtig verstanden hab, verkauft Immune Response heut 2,4 Mio Aktien zu 6$ das Stück. Deshalb heut in den USA schon über 1Mio gehandelte Aktien.

[Dead_Bull]

Warum?
Kannst Du das näher erläutern? Brauchen die Geld oder was ist los?

[VonHinten]

Hi
Das Geld soll für Die Produktentwiklung und Herstellung seines Krebspreperates verwendet werden.

mfg Blaublut

[penguin13]

Hallo,

@VonHinten
Du meinst wohl eher zur Produktion ihres AIDS-Medikamentes, oder?

Ansonsten hat IMNR gerade ein Patent im Bereich ihrer Arthritis-Forschung bekommen. Der Kurs zieht auch schon mächtig an. Na ja, mal schaun ob der Anstieg nachhaltig ist.
Bis jetzt war es ja nicht der Fall!
Hier auf jeden Fall die Meldung:

The Immune Response Corporation Granted U.S. Patent For Targeting and Vaccinating With T Cell Receptor Peptides

Patent Covers Combination of Key Protein Sequences in Company`s
Investigational Immune-based Product for the Treatment of Rheumatoid Arthritis

CARLSBAD, Calif., Aug. 9 /PRNewswire/ -- The Immune Response Corporation
(Nasdaq: IMNR) announced today that it has received United States Patent
Number 6,090,387 covering methods and compositions relating to its
immune-based technology for the prevention and/or treatment of rheumatoid
arthritis. The patent includes specific claims covering a combination of key
protein sequences (peptides) from the Vbeta 3, Vbeta 14 and Vbeta 17 regions
present on the surface of aberrant T cells associated with joint destruction
in rheumatoid arthritis. By vaccinating with a combination of Vbeta 3, Vbeta
14 and Vbeta 17 peptides, the Company believes its product may inhibit the
disease-associated T cells and may prevent further damage.
"This is a key patent in that it directly covers the composition of IR501,
our investigational therapeutic vaccine in development to treat rheumatoid
arthritis," said Richard Bartholomew, Ph.D., Executive Director, Research
Operations, of The Immune Response Corporation. "The issuance of this patent
serves to further strengthen our comprehensive intellectual property position
in the field of T cell receptor peptide vaccine research."
The Company has successfully completed two Phase 2 clinical trials in
rheumatoid arthritis using this proprietary immune-based therapy. In a Phase
2b clinical trial of 340 rheumatoid arthritis patients with active disease,
the Company`s investigational product demonstrated safety and tolerability,
and suggested a statistically significant treatment effect using criteria
established by the American College of Rheumatology.
Several autoimmune disorders, including rheumatoid arthritis, psoriasis
and multiple sclerosis, result from the proliferation of misdirected T cells
that incorrectly identify and destroy the individual`s own tissue, such as the
lining of joints in rheumatoid arthritis. The Company`s proprietary
technology seeks to identify unique T cell receptors (TCRs), which are
proteins found on the surface of these autoreactive pathogenic T cells.
Patients are then vaccinated with portions of these TCR proteins, called TCR
peptides, which are specific to these autoreactive T cells. The Company
believes that this therapy may induce the immune system to eliminate or
inhibit the aberrant T cells without affecting other normal cells.
The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
immune responses for the treatment of HIV, autoimmune diseases and cancer. In
addition, the Company is developing a targeted non-viral delivery technology
for gene therapy, which is designed to enable the delivery of genes directly
to the liver via intravenous injection.

NOTE: News releases for The Immune Response Corporation are available
through PR Newswire Company News On-Call fax service. For a menu of available
news releases or to retrieve a specific release made by The Immune Response
Corporation, please call 800-758-5804, extension 434675. Please retain these
numbers for future reference. Company information can also be located on the
Internet Web Site: http://www.imnr.com.

This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including, but not limited to, whether our patents will be enforceable,
whether additional clinical trials will be successfully concluded and whether
any potential product(s) will be approved for marketing or be successfully
commercialized and those factors discussed more thoroughly in The Immune
Response Corporation`s SEC filings, including but not limited to its report on
Form 10-K for the year ended December 31, 1999 and subsequent Forms 10-Q. The
Company undertakes no obligation to publicly release the results of any
revisions to these forward-looking statements which may be made to reflect
events or circumstances after the date hereof or to reflect the occurrence of
unanticipated events.

SOURCE The Immune Response Corporation

[[e-mail]]

ein bisschen eigenwerbung kann nicht schaden
Thread: 100 % Chance (Kurzfristig)

ps. die ersten postings sind über eine andere Aktie

[guntis]

Hi

Kann mir jemand verraten wie man auf die Thread-Nr. kommt?!

Danke
guntis

[RCZ]

öffne den Tread nicht mit der Linken, sondern mit der rechten Maustaste anklicken, und dann auf Eigenschaften. dort siehst du dann die Thread Nr. http://www. .... /.../152417...

[dj-cool]

Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Announces Second Quarter 2000 Financial Results
CARLSBAD, Calif., Aug. 10 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today announced its financial results for the quarter ended June 30, 2000. The net loss for the second quarter of 2000 was $5.9 million, or $0.21 per share, compared to a net loss of $6.9 million, or a loss of $0.28 per share, reported in the second quarter of 1999. For the six months ended June 30, 2000, the Company reported a net loss of $5.7 million, or $0.21 per share, compared to a net loss of $8.5 million, or $0.35 per share reported for the six months ended June 30, 1999.

Research related revenue for the quarter ended June 30, 2000 was $312,000 compared to $3.9 million for the same quarter in 1999. For the six months ended June 30, 2000 and 1999, revenues were $3.6 million and $13.1 million, respectively, of which $3.6 million in 2000 and $11.9 million in 1999 were from Agouron Pharmaceuticals, Inc. (``Agouron``), a wholly-owned subsidiary of Pfizer Inc. The decrease in research related revenue was primarily attributed to a $5.0 million milestone payment and two quarterly payments of $3.0 million from Agouron in 1999 versus the final quarterly payment of $3.0 million in the first quarter of 2000.

In addition to research related revenue, the Company received non-research revenue from investment and other income of $3.5 million for the six months ended June 30, 2000 versus $733,000 for the same period in 1999. During the first quarter of 2000, $3.0 million of other revenue was primarily due to the sale of an equity security that was acquired through the licensing of technology and from the sale of undeveloped property.

Operating expenses decreased to $6.2 million for the quarter ended June 30, 2000 from $10.9 million in the second quarter of 1999. The decrease in operating expenses was primarily the result of a decrease in clinical and regulatory expenses along with the Company`s workforce reduction in 1999.

Cash, cash equivalents and short-term investments were $25.2 million at June 30, 2000 compared with $23.1 million at the end of 1999. On August 8, 2000, the Company announced a public offering of 2,400,000 shares of its common stock at a price of $6.00 per share through First Security® Van Kasper and Gruntal & Co., L.L.C. The underwriters have been granted an over- allotment option to purchase up to an additional 360,000 shares.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific immune responses for the treatment of HIV, autoimmune diseases, and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.

NOTE: News releases are available through PR Newswire Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: http://www.imnr.com.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including the uncertainty of successful completion of clinical trials, and those risks set forth from time to time in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1999. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


SELECTED FINANCIAL DATA ATTACHED


The Immune Response Corporation
Condensed Consolidated Statements of Operations
(Amount in thousands, except share data)
(unaudited)

Three months ended Six months ended
June 30, June 30,
2000 1999 2000 1999

Research revenue $312 $3,894 $3,645 $13,100

Expenses:
Research and
development 5,131 8,887 10,192 18,437
General and
administrative 1,048 1,402 2,154 2,764
Restructuring costs -- 650 -- 650
6,179 10,939 12,346 21,851
Other revenue:
Investment income 266 353 2,789 733
Other income 4 -- 736 --

Net loss (5,597) (6,692) (5,176) (8,018)

Accretion of preferred
stock (70) (70) (140) (140)
Dividends on preferred
stock (187) (187) (373) (372)

Net loss applicable to
common stockholders $(5,854) $(6,949) $(5,689) $(8,530)

Net loss per share -
basic and diluted $(0.21) $(0.28) $(0.21) $(0.35)

Weighted average number
of shares outstanding 27,369,429 24,509,546 27,139,937 24,325,112


The Immune Response Corporation
Condensed Consolidated Balance Sheets
(Dollars in thousands)

June 30, December 31,
2000 1999
(unaudited)
Assets
Cash, cash equivalents and
short-term investments $25,234 $23,087
Other current assets 462 202
25,696 23,289

Property and equipment, net 9,159 10,760
Licensed technology 4,592 4,945
Other assets 847 1,003

Total assets $40,294 $39,997

Liabilities and stockholders`
equity
Current liabilities $4,193 $8,603
Equipment notes payable 2,146 1,221
Redeemable convertible preferred
stock 9,767 9,627
Stockholders` equity 24,188 20,546

Total liabilities and
stockholders` equity $40,294 $39,997

SOURCE: The Immune Response Corporation